RichyAgajanianMD

Oncology • Downey, CA

Physician

Join to view full profile

Dr. Agajanian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Agajanian's full profile

Already have an account?

Office
11480 Brookshire Ave
Ste 309
Downey, CA 90241
Phone+1 562-869-1201

Fax+1 562-869-1281

Education & Training

Olive View/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Olive View/UCLA Medical CenterResidency, Internal Medicine, 1998 - 2001
University of California, Irvine, School of MedicineClass of 1998

Certifications & Licensure

AZ State Medical License 2016 - 2026
MT State Medical License 2022 - 2026
CA State Medical License 2000 - 2025
NV State Medical License 2018 - 2025

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Top MD Consumers Checkbook

Clinical Trials

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Start of enrollment: 2014 Apr 01
Recruiting
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. Start of enrollment: 2016 Mar 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung can...
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued
Journal for Immunotherapy of Cancer. 2024-03-13
15 citations
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
David J Kuter, Kerry A Rogers, Michael A Boxer, Michael Choi, Richy Agajanian
American Journal of Hematology. 2022-06-01
14 citations
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Matthew S. Davids, Owen A. O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske
Blood Advances. 2021-09-21

Abstracts/Posters

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicent...
Richy Agajanian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Value-Based Model Improves End-of-Life Cancer CareDecember 23rd, 2019
End of Life Cancer Care: Lay Health Workers Improved Quality of Life and Reduced CostsSeptember 17th, 2019
Study Demonstrates Significantly Better Quality Cancer Care and Lower Costs with a Value-Based Care Model Implemented by the Oncology Institute and CareMore HealthSeptember 7th, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member